RxDoctor Payments Data

Laurence Silverstein, MD

Geriatric Medicine · Tarzana, CANPI 1588755466

Payments from drug & device makers

$1,948in general payments, 2019–2025

Across 35 payments — averaging $55.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$352
  • Amgen$334
  • Silk Road Medical, Inc.$147
  • Johnson & Johnson$139
  • E.r. Squibb & Sons, L.L.C.$125
  • Pfizer$125
  • plus $725 from 10 others

What the payments were for

  • Food & beverage$1,943100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,948 in reported general payments places this provider in the 80th percentile of 494 geriatric medicine providers in California.

See all geriatric medicine providers in California

Medicare billing

Part B allowed, 2024
$458,985
Medicare patients
569
Services billed
16,852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide148$186,532
JardianceEmpagliflozin62$95,183
JanuviaSitagliptin Phosphate42$65,362
EliquisApixaban42$51,862
MounjaroTirzepatide23$36,234
FarxigaDapagliflozin Propanediol21$32,954
XareltoRivaroxaban17$25,246
TradjentaLinagliptin28$23,902
Repatha SureclickEvolocumab17$15,372
MyrbetriqMirabegron12$13,489
LinzessLinaclotide11$11,970
Atorvastatin Calcium856$8,944
Xigduo XrDapaglifloz Propaned/Metformin12$7,144
Dexlansoprazole DrDexlansoprazole17$5,842
SynthroidLevothyroxine Sodium94$5,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$123$186,532148 claims
Boehringer IngelheimJardiance, Tradjenta$101$119,08590 claims
PfizerEliquis, Paxlovid$125$53,29268 claims
Lilly USA, LLCMounjaro$37$36,23423 claims
Johnson & JohnsonXarelto$139$25,24617 claims
AbbVieLinzess, Synthroid$352$17,351105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 494 geriatric medicine providers in California.

Other geriatric medicine in Tarzana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →